These medications are game-changers, but they are just one component of our comprehensive blueprint
At present, the evidence remains insufficient to recommend GLP-1 receptor agonists specifically for neurodegenerative disease management
Lipohypertrophya thickened, hardened patch of tissuecan reduce medication absorption and indicates you need to rotate sites more consistently
The company brought in net income of nearly $15.8 million, or earnings per share of 6 cents, below Wall Street expectations of 9 cents per share
Kazuyuki Uchida (Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo) for performing the clear immunostaining
Food and Drug Administration (FDA) has approved Eli Lilly and Company's ZepboundTM (tirzepatide) injection, marking it as the first and only obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors